{"nctId":"NCT04700423","briefTitle":"Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration","startDateStruct":{"date":"2021-03-01","type":"ACTUAL"},"conditions":["Trichuriasis","Ascariasis","Hookworm Infections","Helminthes; Infestation, Intestinal"],"count":536,"armGroups":[{"label":"A: moxidectin (8 mg) / albendazole (400 mg)","type":"EXPERIMENTAL","interventionNames":["Drug: moxidectin (8 mg) / albendazole (400 mg)"]},{"label":"B: ivermectin (200 µg/kg) / albendazole (400 mg)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ivermectin (200 µg/kg) / albendazole (400 mg)"]},{"label":"C: albendazole (400 mg)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]"]},{"label":"D: ivermectin (200 µg/kg)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ivermectin (200 µg/kg)"]},{"label":"E: moxidectin (8 mg)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: moxidectin (8 mg)"]}],"interventions":[{"name":"moxidectin (8 mg) / albendazole (400 mg)","otherNames":["Zentel®"]},{"name":"ivermectin (200 µg/kg) / albendazole (400 mg)","otherNames":["Stromectol® / Zentel®"]},{"name":"ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]","otherNames":["Zentel®"]},{"name":"ivermectin (200 µg/kg)","otherNames":["Stromectol®"]},{"name":"moxidectin (8 mg)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged between 12 and 19 years.\n* Written informed consent signed by either parents/caregivers for underage adolescents (aged 12-17 years) or by the participant him/herself (18-19 years of age); and written assent by underage participant.\n* Agree to comply with study procedures, including provision of two stool samples at the beginning (baseline) and on three follow-up assessments (14-21 days, 5-6 weeks and 3 months after treatment).\n* Willing to be examined by a study physician prior to treatment.\n* At least two slides of the quadruple Kato-Katz thick smears positive for T. trichiura and infection intensities of at least 48 EPG.\n\nExclusion Criteria:\n\n* No written informed consent by individual or caregiver and/or no written assent by minors\n* Presence or signs of major systemic illnesses, e.g. body temperature ≥ 38°C, severe anemia (below 80g/l Hb according to WHO) upon initial clinical assessment.\n* History of acute or severe chronic disease.\n* Recent use of anthelmintic drug (within past 4 weeks).\n* Attending other clinical trials during the study.\n* Pregnancy, lactating, and/or planning to become pregnant within the next 6 months.\n* Known allergy to study medications (i.e. albendazole, ivermectin or moxidectin).\n* Taking medication with known interaction on study drugs.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"19 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Egg Reduction Rate Against T. Trichiura","description":"Egg reduction rate is calculated as the relative reduction in the group geometric mean egg output after co-administration of moxidectin/ albendazole and ivermectin/ albendazole assessed at 14-21 days post-treatment compared to the baseline levels.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","spread":null},{"groupId":"OG001","value":"99.0","spread":null},{"groupId":"OG002","value":"86.2","spread":null},{"groupId":"OG003","value":"94.2","spread":null},{"groupId":"OG004","value":"85.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"The observation time for AE starts when the treatment is initiated. Subjects will be kept for observation for at least 3 hours following treatment for any acute AE and. If there is any abnormal finding, the local study physician will perform a full clinical examination and findings will be recorded. An emergency kit will be available on site to treat any medical conditions that warrant urgent medical intervention. Participants will also be interviewed at 3h and 24h as well as retrospectively 14 -21 days, 5-6 weeks and 3 months after treatment about the occurrence of AEs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Superiority in Terms of Cure Rates (CRs)","description":"Assessment of superiority in terms of CRs of the drug combinations compared to their corresponding monotherapies: Arm C: Albendazole (400 mg) Arm D: Ivermectin (200 μg/kg) and Arm E: Moxidectin (8 mg). Cure rates is defined as the percentages of participants treated with Moxidectin (8 mg)/Albendazole (400 mg), Ivermectin (200 μg/kg)/Albendazole (400 mg), Albendazole (400 mg), Ivermectin (200 μg/kg) or Moxidectin (8 mg) who were cured of infections with T. trichiura.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":null},{"groupId":"OG001","value":"54.0","spread":null},{"groupId":"OG002","value":"26.3","spread":null},{"groupId":"OG003","value":"10.5","spread":null},{"groupId":"OG004","value":"11.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Cure Rates Against T. Trichiura","description":"Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":null},{"groupId":"OG001","value":"54.0","spread":null},{"groupId":"OG002","value":"26.3","spread":null},{"groupId":"OG003","value":"10.5","spread":null},{"groupId":"OG004","value":"11.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Extended Effects (Egg Reduction Rate) on Follow-up of T. Trichiura: 5-6 Weeks","description":"Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"98.3","spread":null},{"groupId":"OG002","value":"75.7","spread":null},{"groupId":"OG003","value":"76.9","spread":null},{"groupId":"OG004","value":"85.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Extended Effects (Cure Rate) on Follow-up of T. Trichiura: 5-6 Weeks","description":"Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.4","spread":null},{"groupId":"OG001","value":"46.4","spread":null},{"groupId":"OG002","value":"16.7","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"11.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Extended Effects (Egg Reduction Rate) on Follow-up of T. Trichiura: 3 Months","description":"Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null},{"groupId":"OG001","value":"97.1","spread":null},{"groupId":"OG002","value":"78.2","spread":null},{"groupId":"OG003","value":"55.4","spread":null},{"groupId":"OG004","value":"71.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Extended Effects (Cure Rates) on Follow-up of T. Trichiura: 3 Months","description":"Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.4","spread":null},{"groupId":"OG001","value":"39.5","spread":null},{"groupId":"OG002","value":"11.1","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"9.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Egg Reduction Rates Against Concomitant Soil-transmitted Helminth Infections: Hookworm","description":"Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"97.4","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"61.9","spread":null},{"groupId":"OG004","value":"81.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Cure Rates Against Concomitant Soil-transmitted Helminth Infections: Hookworm","description":"Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"62.9","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"25.0","spread":null},{"groupId":"OG004","value":"32.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Extended Effects (Egg Reduction Rate) on Follow-up of Hookworm: 5-6 Weeks","description":"Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"96.8","spread":null},{"groupId":"OG002","value":"94.6","spread":null},{"groupId":"OG003","value":"57.9","spread":null},{"groupId":"OG004","value":"88.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Extended Effects (Cure Rate) on Follow-up of Hookworm: 5-6 Weeks","description":"Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.9","spread":null},{"groupId":"OG001","value":"61.4","spread":null},{"groupId":"OG002","value":"66.7","spread":null},{"groupId":"OG003","value":"25.0","spread":null},{"groupId":"OG004","value":"42.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Extended Effects (Egg Reduction Rate) on Follow-up of Hookworm: 3 Months","description":"Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null},{"groupId":"OG001","value":"95.1","spread":null},{"groupId":"OG002","value":"96.3","spread":null},{"groupId":"OG003","value":"56.1","spread":null},{"groupId":"OG004","value":"76.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Extended Effects (Cure Rate) on Follow-up of Hookworm: 3 Months","description":"Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.1","spread":null},{"groupId":"OG001","value":"60.0","spread":null},{"groupId":"OG002","value":"66.7","spread":null},{"groupId":"OG003","value":"25.0","spread":null},{"groupId":"OG004","value":"32.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Egg Reduction Rates Against Concomitant Soil-transmitted Helminth Infections: Ascaris Lumbricoides","description":"Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null},{"groupId":"OG004","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cure Rates Against Concomitant Soil-transmitted Helminth Infections: Ascaris Lumbricoides","description":"Cure rates is defined as the percentages of participants treated with Moxidectin (8 mg)/Albendazole (400 mg), Ivermectin (200 μg/kg)/Albendazole (400 mg), Albendazole (400 mg), Ivermectin (200 μg/kg) or Moxidectin (8 mg) who were cured of infections with A. lumbricoides.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"96.4","spread":null},{"groupId":"OG002","value":"91.7","spread":null},{"groupId":"OG003","value":"100.0","spread":null},{"groupId":"OG004","value":"98.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extended Effects (Egg Reduction Rate) on Follow-up of A. Lumbricoides: 5-6 Weeks","description":"Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null},{"groupId":"OG004","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extended Effects (Cure Rate) on Follow-up of A. Lumbricoides: 5-6 Weeks","description":"Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null},{"groupId":"OG004","value":"98.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extended Effects (Egg Reduction Rate) on Follow-up of A. Lumbricoides: 3 Months","description":"Eggs per gram of stool will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null},{"groupId":"OG004","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extended Effects (Cure Rate) on Follow-up of A. Lumbricoides: 3 Months","description":"Cure rates of each treatment will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null},{"groupId":"OG001","value":"88.2","spread":null},{"groupId":"OG002","value":"91.7","spread":null},{"groupId":"OG003","value":"92.9","spread":null},{"groupId":"OG004","value":"87.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":207},"commonTop":["Headache","Abdominal pain","Muscle weakness","Musculoskeletal pain","Itching"]}}}